Get the Stockscreener App
14.04
1.20%
-0.17
After Hours:
14.04
Adaptive Biotechnologies Corp stock is traded at $14.04, with a volume of 1.23M.
It is down -1.20% in the last 24 hours and up +13.13% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
See More
Previous Close:
$14.21
Open:
$14.21
24h Volume:
1.23M
Relative Volume:
0.64
Market Cap:
$2.24B
Revenue:
$276.98M
Net Income/Loss:
$-59.46M
P/E Ratio:
-35.21
EPS:
-0.3987
Net Cash Flow:
$-48.95M
1W Performance:
-1.20%
1M Performance:
+13.13%
6M Performance:
-16.92%
1Y Performance:
+80.69%
1-Day Range:
$13.71
$14.30
1-Week Range:
$13.50
$14.55
52-Week Range:
$7.16
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
14.04 | 2.27B | 276.98M | -59.46M | -48.95M | -0.3987 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means - AOL.com
Time To Buy? Stock Analysis: NIO, XPeng XPEV, Costco, Adaptive Biotechnologies ADPT, GE (JtamyA8uVU) - Fathom Journal
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock By Investing.com - Investing.com Canada
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock - Investing.com
Adaptive Biotechnologies (ADPT) president sells 57K shares, exercises options - Stock Titan
[ARS] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) 2026 proxy details and 2025 performance - Stock Titan
Adaptive Biotechnologies COO Julie Rubinstein sells $1.01m in stock By Investing.com - Investing.com India
Adaptive Biotechnologies COO Julie Rubinstein sells $1.01m in stock - Investing.com
Adaptive Biotechnologies (ADPT) COO sells shares, exercises options under 10b5-1 plan - Stock Titan
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? - AOL.com
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies - Intellectia AI
Adaptive Biotechnologies: Strong Sequencing, Weak Margin Of Safety (NASDAQ:ADPT) - Seeking Alpha
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares? - The Motley Fool
Is Adaptive Bio (ADPT) stock stronger than peers (Investor Interest) 2026-04-18Investment Signal Network - Cổng thông tin điện tử tỉnh Lào Cai
Adaptive Biotechnologies Hits Day Low of $13.37 Amid Price Pressure - Markets Mojo
Adaptive Biotechnologies president Rubinstein sells $826k in ADPT stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies president Rubinstein sells $826k in ADPT stock - Investing.com
Adaptive Biotechnologies (ADPT) COO exercises options and sells 57,180 shares - Stock Titan
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 - The Manila Times
Adaptive Biotechnologies schedules May 5 webcast for Q1 2026 results - Stock Titan
Adaptive Biotechnologies getting closer to key technical measure - MSN
Adaptive Biotechnologies (ADPT) moves 5.8% higher: Will this strength last? - MSN
Adaptive Biotechnologies (ADPT) president Rubinstein sells $758k in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies (ADPT) president Rubinstein sells $758k in stock - Investing.com
Adaptive Biotechnologies (NASDAQ: ADPT) COO sells shares under 10b5-1 plan - Stock Titan
Robins, Adaptive Biotechnologies CSO, sells $148,500 in stock By Investing.com - Investing.com Australia
Insider Sell: Harlan Robins Sells Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Adaptive Biotechnologies (ADPT) chief people officer sells $340k in stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) chief people officer sells $340k in stock - Investing.com Australia
Robins, Adaptive Biotechnologies CSO, sells $148,500 in stock - Investing.com
Adaptive Biotechnologies (ADPT) officer sells shares after option exercise - Stock Titan
Adaptive Biotechnologies (NASDAQ: ADPT) CSO sells 10,000 shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies Corp. Opens with a 9.41% Gain, Outperforming S&P 500 - Markets Mojo
Adaptive Biotechnologies Hits Day High with 8.24% Surge in Stock Price - Markets Mojo
Why Adaptive Biotechnologies Stock Is Sinking Today - TipRanks
Insider Sell: Chad Robins Sells 120,595 Shares of Adaptive Biote - GuruFocus
Adaptive Biotechnologies president Rubinstein sells $990k in ADPT stock By Investing.com - Investing.com India
Adaptive Biotechnologies CEO Robins sells $1.76m in ADPT stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies president Rubinstein sells $990k in ADPT stock - Investing.com
[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity - Stock Titan
ADPT COO Rubinstein sells shares, exercises options under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adaptive Biotechnologies Corp Stock (ADPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RUBINSTEIN JULIE | President and COO |
Apr 23 '26 |
Option Exercise |
8.46 |
14,722 |
124,548 |
405,530 |
| RUBINSTEIN JULIE | President and COO |
Apr 24 '26 |
Option Exercise |
8.46 |
14,722 |
124,548 |
401,192 |
| RUBINSTEIN JULIE | President and COO |
Apr 22 '26 |
Sale |
14.13 |
19,060 |
269,318 |
390,808 |
| RUBINSTEIN JULIE | President and COO |
Apr 24 '26 |
Sale |
14.02 |
19,060 |
267,221 |
382,132 |
| RUBINSTEIN JULIE | President and COO |
Apr 23 '26 |
Sale |
13.74 |
19,060 |
261,884 |
386,470 |
| RUBINSTEIN JULIE | President and COO |
Apr 21 '26 |
Option Exercise |
10.10 |
26,603 |
268,783 |
426,087 |
| RUBINSTEIN JULIE | President and COO |
Apr 17 '26 |
Option Exercise |
8.46 |
14,722 |
124,548 |
422,882 |
| RUBINSTEIN JULIE | President and COO |
Apr 20 '26 |
Option Exercise |
8.46 |
14,722 |
124,548 |
418,544 |
| RUBINSTEIN JULIE | President and COO |
Apr 21 '26 |
Sale |
14.66 |
30,941 |
453,595 |
395,146 |
| RUBINSTEIN JULIE | President and COO |
Apr 17 '26 |
Sale |
14.57 |
19,060 |
277,704 |
403,822 |
0.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):